Bulk Pharmaceutical API Sources for voriconazole

Bulk Pharmaceutical API Sources for voriconazole

Vendor	Vendor Homepage	Vendor Sku	API Url
NIH Clinical Collection		SAM001246664
Hangzhou Trylead Chemical Technology		TL8000858
NovoSeek		71616
MolPort		MolPort-003-850-863
Hangzhou APIChem Technology		AC-823

Bulk API Sources for Voriconazole

Last updated: February 20, 2026

Voriconazole is a triazole antifungal agent used to treat serious fungal infections. Its global supply chain depends on multiple API manufacturers, primarily located in Asia, Europe, and North America, with a concentration of production in China and India.

Leading API Manufacturers of Voriconazole

Manufacturer	Location	Production Capacity	Certification & Compliance	Notable Certifications	Supply Status
Jiangsu Hengrui Medicine Co.	China	Estimated high	GMP, DMF, COS	EU GMP, US FDA inspection passed	Active, large scale
Wuhan Phytopharm Co.	China	Estimated moderate	GMP	ISO 9001, DMF	Active
Zhejiang Huiji Pharmaceutical	China	Estimated moderate	GMP, DMF	CE, US FDA approved	Active
Novartis AG	Switzerland	Proprietary sourcing	GMP, cGMP	FDA, EMA approvals	Limited, contract manufacturing
Biocon Limited	India	Emerging capacity	WHO GMP, ISO 9001	DMF, USFDA inspections	Growing, primary supplier in India
Dr. Reddy’s Laboratories	India	Significant capacity	GMP, US FDA, ISO 9001	Multiple DMFs	Active

Primary Production Regions and Market Dynamics

• China: Dominates in API manufacturing due to lower costs and sizable manufacturing infrastructure. Major players include Jiangsu Hengrui and Zhejiang Huiji. Production often occurs in facilities certified to GMP, with many holding US FDA and EU compliance.
• India: Increasing API capacity, notably by Biocon and Dr. Reddy’s. These firms meet WHO GMP standards and actively supply globally.
• Europe & North America: Production here focuses on finished dosage production and sometimes API supply for specialized or regulated markets, primarily through multinational pharmaceutical companies like Novartis.

Certification and Regulatory Status

• Most API producers for voriconazole possess GMP certification, with some holding US FDA and EMA approval.
• Many manufacturers maintain DMFs in the US and Europeans have certifying documentation aligned with cGMP standards.
• Some manufacturers have been inspected by regulatory authorities, enhancing legitimacy and export viability.

Supply Chain Considerations

• Market reliance: >70% of the world's API supply for voriconazole emanates from China and India.
• Supply risks: Geopolitical issues, trade restrictions, and pandemic-related disruptions have intermittently impacted supply stability.
• Pricing dynamics: API costs fluctuate with manufacturing capacity, regulatory approvals, and raw material costs, influencing finished product pricing.

Recent Trends and Developments

• API manufacturers are increasingly investing in capacity expansion, especially in India and China.
• Regulatory scrutiny has intensified, leading to higher certification requirements.
• Some large pharmaceutical firms are moving toward high-quality, locally sourced API production to meet stricter regional regulations.

Summary Points

• Most bulk API for voriconazole originates in China and India.
• Major manufacturers include Jiangsu Hengrui, Biocon, Dr. Reddy’s, and Wuhan Phytopharm.
• Certification levels range from GMP to US FDA-approved facilities.
• Supply is generally stable but vulnerable to geopolitical and economic factors.
• Analyzing supplier capacity, certification, and compliance status influences procurement decisions.

Key Takeaways

• The API supply for voriconazole is concentrated in Asia, with increasing capacities.
• Certifications like GMP, US FDA, and EU approval are critical for market access.
• Supply chain risks include geopolitical tensions, regulatory changes, and pandemic disruptions.
• Manufacturers with established certification and capacity are preferred for long-term sourcing.
• Monitoring regulatory compliance and capacity expansion informs procurement strategy.

FAQs

1. Which countries dominate voriconazole API manufacturing?
China and India lead in production. China accounts for the bulk of global API manufacturing, followed by India, which is expanding capacity.

2. What certifications are essential for voriconazole API suppliers?
Good Manufacturing Practice (GMP) certification, with US FDA and EU approval, are critical for compliance in regulated markets.

3. Are there supply risks associated with Chinese API manufacturers?
Yes, geopolitical tensions and trade restrictions can affect supply stability, although many Chinese manufacturers maintain high-quality standards.

4. How does API sourcing impact drug pricing?
API costs directly influence finished drug prices; higher quality and certified sources tend to command premiums but reduce regulatory and supply risks.

5. What recent trends are shaping voriconazole API supply?
Capacity expansion in India and China, stricter regulatory oversight, and quality improvements are key trends influencing the API market.

---

References

1. U.S. Food and Drug Administration. (2022). Drug Master Files (DMFs). https://www.fda.gov/drugs/drug-approvals-and-databases/drug-master-files-dmfs
2. European Medicines Agency. (2022). Guidelines on Good Manufacturing Practice. https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice
3. IQVIA Institute. (2022). The Global API Market Report.
4. PharmSource. (2022). API Manufacturing Trends and Market Data.[1]